Evidence map›Paper›PMID 36523982›Full record

ArticleFrontiers in oncology2022

Single-cell analyses reveal the therapeutic effects of ATHENA and its mechanism in a rhabdomyosarcoma patient.

Yujun Liu, Ke Wang, Yanli Zhou, Xibing Zhuang, Shali Shao, Fulu Qiao, Xiangdong Wang, Xin Zou, Tiankui Qiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yujun LiuCenter for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Ke WangCenter for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Yanli ZhouNuclear Medicine Department, Jinshan Hospital, Fudan University, Shanghai, China.
Xibing ZhuangCenter for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Shali ShaoCenter for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Fulu QiaoDepartment of Breast Surgery, Tai'an Central Hospital, Tai'an, China.
Xiangdong WangCenter for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Xin ZouCenter for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Tiankui QiaoCenter for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Jinshan Hospital of Fudan University · CNTaian City Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Whole-cell tumor vaccines tend to suffer from low immunogenicity. Our previous study showed that irradiated lung cancer cell vaccines in mouse models enhance antitumor efficacy by eliciting an intensive T cells response and improving immunogenicity. Based on these findings, we developed an improved whole-cell tumor vaccine, Autologous Tumor Holo antigEn immuNe Activation (ATHENA). Methods: In this study, we report the successful treatment of a 6-year-old male diagnosed with meningeal rhabdomyosarcoma with pulmonary and liver metastases using ATHENA. After 6 cycles of therapy, PET/CT showed the therapeutic efficacy of ATHENA. We profiled the immune response by single-cell RNA sequencing (scRNA-seq). Flow cytometry analysis was implemented to validate the status transitions of CD8 Results: In CD8 Conclusion: Such studies not only show that ATHENA therapy may be a promising alternative treatment for tumor patients but provide a novel idea to analyses the mechanisms of rare cases or personalized cancer treatment.

Indexed as

autologous tumor vaccinesB cellscentral memoryexhausted statescSTARsingle-cell RNA sequencingT cells

Identifiers

PMID36523982
PMCPMC9745782
OpenAlexW4310239168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.